Herpes Zoster Keratoconjunctivitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for herpes zoster keratoconjunctivitis. 32 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
32
Active US patents
42/100
Avg vulnerability
—
Annual revenue covered

Originators in Herpes Zoster Keratoconjunctivitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 32 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating herpes zoster keratoconjunctivitis. Each bar = one year. Y-axis scaled to peak year (30 patents).

30
33
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lotemax
LOTEPREDNOL ETABONATE
 Bausch Health 32 42 — 2033-05-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12115246 Lotemax method of use 58 2033-05-03
12115246 Lotemax method of use 58 2033-05-03
11596599 Lotemax method of use 53 2033-05-03
11219596 Lotemax method of use 53 2033-05-03
11219597 Lotemax method of use 53 2033-05-03
11534395 Lotemax method of use 53 2036-01-26
10993908 Lotemax method of use 45 2033-05-03
9056057 Lotemax method of use 45 2033-05-03
10058511 Lotemax method of use 45 2033-05-03
9532955 Lotemax method of use 45 2033-05-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10688045 Lotemax formulation 25 2033-05-03
10646436 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
10646437 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
11642317 Lotemax formulation 33 2033-05-03
11642317 Lotemax formulation 33 2033-05-03
11872318 Lotemax formulation 38 2033-05-03
11872318 Lotemax formulation 38 2033-05-03

Related